COMMUNIQUÉS West-GlobeNewswire

Medicana Health Group Celebrates Two Major Recognitions in Capital Magazine’s CSR Research
15/06/2026
“Next Stop: Mammography” is ranked among Türkiye’s top 20 corporate social responsibility projects, while Medicana Health Group is listed among the top five companies in the Health category Photo: A coastal bicycle tour [...]
Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
15/06/2026
SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ CUPR ” or “the Company ”), a biomedical company developing and marketing products for the chronic wounds, infertility, [...]
Le KFSH montre comment les hôpitaux spécialisés peuvent stimuler l’innovation au sein des systèmes de santé lors du congrès HLTH Europe 2026
15/06/2026
AMSTERDAM, 15 juin 2026 (GLOBE NEWSWIRE) -- À l’occasion de son parrainage et de sa participation au congrès HLTH Europe 2026, qui se tiendra du 15 au 18 juin à Amsterdam, le King Faisal Specialist Hospital & [...]
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
15/06/2026
Company at a Turning Point — Moving the Business to a Different Level, With Growing Revenue and a Roadmap Toward Improved Profitability CHICAGO, June 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or [...]
BioSyent to Present at Planet MicroCap Las Vegas
15/06/2026
MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada [...]
Cardiawave Announces First Routine Treatments Performed with Valvosoft® Following CE Mark Approval and Accelerates Its Deployment
15/06/2026
Cardiawave Announces First Routine Treatments Performed with Valvosoft® Following CE Mark Approval and Accelerates Its Deployment After demonstrating its safety and performance in more than 100 patients during clinical [...]
IBA – ACQUISITION D’ACTIONS PROPRES
15/06/2026
Louvain-la-Neuve, Belgique, 15 juin 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
15/06/2026
Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution RENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- [...]
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
15/06/2026
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX’s platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including [...]
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
15/06/2026
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, [...]
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
15/06/2026
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual meeting. The poster [...]
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
15/06/2026
Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 [...]
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
15/06/2026
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as [...]
Porosome Therapeutics Announces Global Drug Development Partnership with the Largest Governmental R&D Organization in India
15/06/2026
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Porosome Therapeutics, Inc., announced today that it has entered into a drug development partnership with the Council of Scientific and Industrial Research (CSIR) of the [...]
Le KFSH met en avant la transformation des prestataires grâce à un impact opérationnel mesurable au HLTH Europe 2026
15/06/2026
AMSTERDAM, 15 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) véhicule un message de transformation pratique des prestataires lors de sa participation au HLTH Europe 2026, [...]
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15/06/2026
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function Raanana, Israel [...]
Sienna Announces June Dividend
15/06/2026
MARKHAM, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
KFSH Highlights Provider Transformation Through Measurable Operational Impact at HLTH Europe 2026
15/06/2026
AMSTERDAM, June 15, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is bringing a practical provider-transformation message during its participation at HLTH Europe 2026, taking [...]
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
15/06/2026
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury [...]

Pages